Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review ; volume:36 ; number:1 ; day:27 ; month:5 ; year:2024 ; pages:1-11 ; date:12.2024
Journal of the Egyptian National Cancer Institute / Egyptian National Cancer Institute; 36, Heft 1 (27.5.2024), 1-11, 12.2024
- Urheber
-
Mulyadi, Rahmad
Hasan, Irsan
Sidipratomo, Prijo
Putri, Pungky Permata
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43046-024-00224-4
- URN
-
urn:nbn:de:101:1-2407012112388.267521694261
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mulyadi, Rahmad
- Hasan, Irsan
- Sidipratomo, Prijo
- Putri, Pungky Permata
- SpringerLink (Online service)
Ähnliche Objekte (12)
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Transarterial Chemoembolization – Status Quo in Germany
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)
Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Combined Transarterial Chemoembolization and Percutaneous Ablation: A Single-Center Experience
Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Transarterial Chemoembolization – Status Quo in Germany
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)
Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Combined Transarterial Chemoembolization and Percutaneous Ablation: A Single-Center Experience
Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Transarterial Chemoembolization – Status Quo in Germany
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)
Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Combined Transarterial Chemoembolization and Percutaneous Ablation: A Single-Center Experience